Cargando…

Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD

Detalles Bibliográficos
Autores principales:	Hong, Simon J., Bhattacharya, Sumona, Aboubakr, Aiya, Nadkarni, Devika, Lech, Diana, Ungaro, Ryan C., Agrawal, Manasi, Hirten, Robert, Greywoode, Ruby, Mone, Anjali, Chang, Shannon, Hudesman, David, Ullman, Thomas, Sultan, Keith S., Lukin, Dana J., Colombel, Jean Frederic, Axelrad, Jordan E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212637/ http://dx.doi.org/10.1016/S0016-5085(22)61404-5

Ejemplares similares

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case–control study
por: Hong, Simon J., et al.
Publicado: (2022)

Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY
por: Agrawal, Manasi, et al.
Publicado: (2021)

Fr491 MULTIVARIABLE PREDICTION MODELS FOR HOSPITALIZATION, VENTILATION, AND DEATH FROM COVID-19 IN IBD PATIENTS
por: Sperger, John, et al.
Publicado: (2021)

Fr098 IMPACT OF COVID-19 PANDEMIC IN IBD PATIENT CARE
por: Dahiya, Monica, et al.
Publicado: (2021)

Mo1087: MALADAPTIVE BEHAVIORS IN PERSONS WITH IBD DURING THE COVID-19 PANDEMIC
por: Shaffer, Seth R., et al.
Publicado: (2022)

The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2021)

Su1494: REDUCED SEROLOGICAL RESPONSE TO COVID-19 VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; EARLY RESULTS OF THE VARIATION STUDY (VARIABILITY IN RESPONSE IN IBD AGAINST SARS-COV2-IMMUNISATION)
por: Doherty, Jayne, et al.
Publicado: (2022)

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2020)

Sa1055: PERCEPTIONS OF ACCESSING CARE AMONG IBD PATIENTS DURING THE COVID-19 PANDEMIC
por: Shaffer, Seth R., et al.
Publicado: (2022)

Fr493 DISEASE ACTIVITY IS ASSOCIATED WITH COVID-19 OUTCOMES IN IBD PATIENTS WITH EFFECT MODIFICATION BY AGE
por: Ricciuto, Amanda, et al.
Publicado: (2021)

Su1496: SARS-COV-2 INFECTION IN IBD: PANDEMIC WAVES AND PREDICTORS OF SEVERE OR PERSISTENT COVID-19
por: Taxonera, Carlos, et al.
Publicado: (2022)

Su102 DIFFERENCES IN INTESTINAL EPITHELIAL GENE EXPRESSION MODULATES SARS-COV-2 INFECTION IN HUMAN IBD ENTEROIDS
por: Alvarado, David M., et al.
Publicado: (2021)

Su1497: EFFECT OF SARS COV-2 VACCINE IN IBD PATIENTS ON BIOLOGIC THERAPY INCLUDING LIVER TRANSPLANT RECIPIENTS.
por: Brezina, Jan, et al.
Publicado: (2022)

Fr497 INCIDENCE AND OUTCOMES OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Khan, Shahab R., et al.
Publicado: (2021)

EP1021: CHANGES IN THE NEEDS OF IBD PATIENTS FOR TREATMENT BEFORE AND AFTER THE COIVD19 EPIDEMIC (ANALYSIS USING TWITTER DATA)
por: Fuchigami, Ayako
Publicado: (2022)

Mo1086: MENTAL HEALTH IN IBD DURING THE COVID-19 PANDEMIC: ACCESS TO MENTAL HEALTH CARE AND EXPOSURE TO PANDEMIC NEWS
por: Shaffer, Seth R., et al.
Publicado: (2022)

Sa1061: CROSS-SECTIONAL AND LONGITUDINAL ASCERTAINMENT OF PATIENTS WITH IBD'S PERCEPTIONS AND EXPERIENCES DURING COVID-19: CLAPPED COVID-19
por: Lee, Hanbich, et al.
Publicado: (2022)

Sa081 FEAR OF COVID-19 AMONG IBD PATIENTS ACCORDING TO EMPLOYMENT STATUS, EDUCATION AND RESIDENCE AND COMPARED TO OTHER GI CONDITIONS
por: Lo, Bobby, et al.
Publicado: (2021)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Su095 REAL-TIME DEFORMABILITY CYTOMETRY (RT-DC) REVEALS NOVEL CORRELATIONS BETWEEN INFLAMMATION AND MECHANICAL PROPERTIES OF NEUTROPHILS IN IBD PATIENTS
por: Ganzleben, Ingo, et al.
Publicado: (2021)

Sa127 AN IBD-RISK VARIANT IN PTPN2 PROMOTES CELLULAR UPTAKE OF SARS-COV-2, WHICH IS MITIGATED BY THE JAK INHIBITOR TOFACITINIB
por: Spalinger, Marianne, et al.
Publicado: (2021)

855 PATIENT-LED REMOTE INTRACAPILLARY PHARMACOKINETIC SAMPLING (FINGERPRICKS): VALIDATION AND ACCEPTABILITY FOR HOME THERAPEUTIC DRUG MONITORING IN PATIENTS WITH IBD IN THE COVID-19 PANDEMIC
por: Chee, Desmond, et al.
Publicado: (2021)

Sa1050: COVID-19 VACCINATION RATES AND POST-VACCINATION INFECTION RISK IN IBD PATIENTS TREATED WITH DISEASE MODIFYING AGENTS: A RESEARCH NETWORK ANALYSIS
por: Chumbe, Julton Tomanguillo, et al.
Publicado: (2022)

Fr496 THE EFFECTS OF COMORBIDITIES ON COVID-19 OUTCOMES AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Parekh, Rajen, et al.
Publicado: (2021)

Fr498 NEW GASTROINTESTINAL SYMPTOMS ARE COMMON IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH COVID-19: DATA FROM AN INTERNATIONAL REGISTRY
por: Ungaro, Ryan C., et al.
Publicado: (2021)

IBD in the COVID-19 era: the value of international collaboration
por: Brenner, Erica J, et al.
Publicado: (2020)

Fr509 COVID-19 OUTCOMES AMONG RACIAL AND ETHNIC MINORITY INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASES IN THE UNITED STATES
por: Agrawal, Manasi, et al.
Publicado: (2021)

Su1493: COVID-19 RELATED THROMBOTIC, CARDIOVASCULAR, AND RENAL COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY
por: Spiera, Emily, et al.
Publicado: (2022)

Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD
por: Sperger, John, et al.
Publicado: (2021)

Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients
por: Sperger, John, et al.
Publicado: (2021)

Preclinical IBD: One more piece of the puzzle
por: Agrawal, Manasi, et al.
Publicado: (2023)

Managing IBD in the COVID-19 era
por: Scalzo, Nicholas, et al.
Publicado: (2023)

Sa502 THE FIRST AND SECOND WAVE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A TEMPORAL TREND ANALYSIS
por: Kaplan, Gilaad, et al.
Publicado: (2021)

Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States
por: Hong, Simon J, et al.
Publicado: (2021)

Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists
por: Bilal, Mohammad, et al.
Publicado: (2017)

Mo1020: GUT MICROBIOME CHANGES ASSOCIATED WITH HIGHER AND LONGER-LASTING ANTIBODY TITERS FOLLOWING COVID-19 VACCINATION
por: Venzon, Mericien M., et al.
Publicado: (2022)

COVID-19 in IBD: The experience of a single tertiary IBD center
por: Rizzello, Fernando, et al.
Publicado: (2021)

Zebrafish model for IBD
Publicado: (2011)

IBD considerations in spondyloarthritis
por: Di Jiang, Caroline, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ra3n8k4m9o00huaq9ies62bp0n